Skip to Main Content

Paper Details

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
Oncology
65
2011

Datasets

Release 1.2